Automated chain-of-custody systems save $1.3m per clinical trial: Almac

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags Almac clinical technologies Automation

Using automated chain-of-custody systems can save study sponsors and CROs a minimum of $1.3m per clinical trial in operating costs, according to a recent report from Almac.

To determine the time spent on reconciling supplies, resolving discrepancies, and completing close-out activities, Almac Clinical Technologies – a member of the Almac Group – surveyed clinical trial personnel involved in the accountability and reconciliation process.

The research compared manual paper-based processes against electronic, as well as a hybrid approach of both.

According to the report, automation, on average, reduces time spent when reconciling supplies by 87%, or approximately 32 minutes per drug kit. It also cuts the time spent per trial on close-out activities and reports as it pertains to accountability and reconciliation by 35%.

Additionally, because it reduces the amount of time monitors spent at clinical sites to complete various activities, the report suggests a further average savings of $435,456 per study.

Almac estimated automated drug accountability and reconciliation systems can in total save a company a minimum of $1.3m per trial in tangible costs.

Matthew Cocking, marketing director, Almac Clinical Technologies, said the results were surprisingly positive. “The data revealed a drastic decrease in time and effort spent on this area as a result of utilizing an electronic solution for drug accountability and reconciliation,”​ he told us.

“We view the results of this as very positive for everyone involved in these areas of clinical development. By employing an automated solution for drug accountability and reconciliation, the evidence is clear that this approach will provide meaningful cost-savings to sponsors and CROs during the course of a clinical trial,”​ said Cocking.

As Cocking explained, if the data are not logged accurately, the drug accountability and reconciliation processes may “inevitably result in lengthy investigations, often delaying study closeout.”

He added, “Furthermore, as some clinical sites still employ a paper-based approach as part of their standard operating procedures, we view this data as a great incentive to collaborate with trial-sponsors to work together towards updating their processes in order to reduce the burden on site coordinators as well.” 

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more